27 62

Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer

Authors
 Ji Yeon Lee  ;  Namki Hong  ;  Hye Ryun Kim  ;  Byung Wan Lee  ;  Eun Seok Kang  ;  Bong Soo Cha  ;  Yong Ho Lee 
Citation
 Endocrinology and Metabolism (대한내분비학회지), Vol.33(1) : 97-104, 2018 
Journal Title
 Endocrinology and Metabolism (대한내분비학회지) 
ISSN
 2093-596X 
Issue Date
2018
Keywords
Cachexia ; Parathyroid hormone-related peptide ; Weight loss
Abstract
BACKGROUND: A recent animal study showed that parathyroid hormone-related peptide (PTHrP) is associated with cancer cachexia by promoting adipose tissue browning, and we previously demonstrated that PTHrP predicts weight loss (WL) in patients with cancer. In this study, we investigated whether prediction of WL by PTHrP is influenced by clinical factors such as serum albumin, corrected calcium levels, cancer stage, and performance status (PS). METHODS: A cohort of 219 patients with cancer whose PTHrP level was measured was enrolled and followed for body weight (BW) changes. Subjects were divided into two groups by serum albumin (cutoff value, 3.7 g/dL), corrected calcium (cutoff value, 10.5 mg/dL), cancer stage (stage 1 to 3 or 4), or PS (Eastern Cooperative Oncology Group 0 to 1 or 2 to 4), respectively. Clinically significant WL was defined as either percent of BW change (% BW) <-5% or % BW <-2% plus body mass index (BMI) <20 kg/m(2). RESULTS: After a median follow-up of 327 days, 74 patients (33.8%) experienced clinically significant WL. A positive PTHrP level was associated with a 2-fold increased risk of WL after adjusting for age, baseline BMI, serum albumin, corrected calcium level, cancer stage, and PS. The effect of PTHrP on WL remained significant in patients with low serum albumin, stage 4 cancer, and good PS. Regardless of calcium level, the effect of PTHrP on WL was maintained, although there was an additive effect of higher calcium and PTHrP levels. CONCLUSION: Early recognition of patients with advanced cancer who are PTHrP positive with hypercalcemia or hypoalbuminemia is needed for their clinical management.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/162490
Files in This Item:
T201801737.pdf Download
DOI
10.3803/EnM.2018.33.1.97
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
강은석(Kang, Eun Seok) ORCID logo https://orcid.org/0000-0002-0364-4675
김혜련(Kim, Hye Ryun) ORCID logo https://orcid.org/0000-0002-1842-9070
이병완(Lee, Byung Wan)
이용호(Lee, Yong Ho) ORCID logo https://orcid.org/0000-0002-6219-4942
이지연(Lee, Ji Yeon)
차봉수(Cha, Bong Soo) ORCID logo https://orcid.org/0000-0003-0542-2854
홍남기(Hong, Namki) ORCID logo https://orcid.org/0000-0002-8246-1956
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse